000 03817cam a22006491i 4500
001 9781003045397
003 FlBoTFG
005 20260210180830.0
006 m d
007 cr |||||||||||
008 200724s2021 si a ob 000 0 eng d
040 _aOCoLC-P
_beng
_erda
_epn
_cOCoLC-P
020 _a9781003045410
_q(electronic bk.)
020 _a1003045413
_q(electronic bk.)
020 _a9781000067392
_q(electronic bk. : Mobipocket)
020 _a1000067394
_q(electronic bk. : Mobipocket)
020 _a9781000067385
_q(electronic bk. : PDF)
020 _a1000067386
_q(electronic bk. : PDF)
020 _a9781000067378
_qelectronic publication
020 _a1000067378
_qelectronic publication
020 _a9781000067354
_qelectronic book
020 _a1000067351
_qelectronic book
020 _a9781000067361
_qMobipocket electronic book
020 _a100006736X
_qMobipocket electronic book
020 _a9781003045397
_qelectronic book
020 _a1003045391
_qelectronic book
020 _z9789814877138
_qhardcover
024 7 _a10.1201/9781003045397
_2doi
035 _a(OCoLC)1202850119
035 _a(OCoLC-P)1202850119
050 4 _aTP248.E5
_bP53 2021
072 7 _aMED
_x072000
_2bisacsh
072 7 _aSCI
_x010000
_2bisacsh
072 7 _aSCI
_x013000
_2bisacsh
072 7 _aMQP
_2bicssc
082 0 4 _a660.634
_223
245 0 0 _aPharmaceutical biocatalysis :
_bimportant emzymes, novel targets, and therapies /
_cedited by Peter Grunwald.
264 1 _aSingapore :
_bJenny Stanford Publishing,
_c[2021]
300 _a1 online resource :
_billustrations (black and white, and colour).
336 _atext
_2rdacontent
336 _astill image
_2rdacontent
337 _acomputer
_2rdamedia
338 _aonline resource
_2rdacarrier
490 0 _aJenny Stanford series on biocatalysis ;
_vvolume 6
520 _aThis volume of Pharmaceutical Biocatalysis starts with a discussion on the importance of biocatalytic synthesis approaches for a sustainable and environmentally friendly production of pharmaceuticals and active pharmaceutical ingredients. Among the enzymes discussed in detail with respect to their pharmaceutical relevance are cyclic nucleotide phosphodiesterases playing an important role in modulating signal transduction in various cell types; human DOPA decarboxylase, related to Parkinson's disease and aromatic amino acid decarboxylase deficiency; and phospholipase D enzymes as drug targets. Isocitrate dehydrogenase 1 and 2 mutations are novel therapeutic targets in acute myeloid leukemia. An additional chapter is devoted to the use of enzymes for prodrug activation in cancer therapy. The other topics include small-molecule inhibitors targeting receptor tyrosine kinases in cancer, -Lactams and related compounds as antibacterials, non-vitamin K oral anticoagulants for the treatment of thromboembolic diseases, and the molecular mechanisms for statin pleiotropy and its clinical relevance in cardiovascular diseases. The last chapter is a review of lysosomal storage disorders with an overview of approved drugs for treating these disorders by enzyme replacement therapy.
588 _aOCLC-licensed vendor bibliographic record.
650 0 _aEnzymes
_xIndustrial applications.
650 0 _aBiocatalysis.
650 0 _aPharmaceutical chemistry.
_91974
650 7 _aMEDICAL / Pharmacy
_2bisacsh
650 7 _aSCIENCE / Biotechnology
_2bisacsh
650 7 _aSCIENCE / Chemistry / General
_2bisacsh
700 1 _aGrunwald, Peter,
_d1941-
_eeditor.
856 4 0 _3Taylor & Francis
_uhttps://www.taylorfrancis.com/books/9781003045397
856 4 0 _3Taylor & Francis
_uhttps://www.taylorfrancis.com/books/9781003045410
856 4 2 _3OCLC metadata license agreement
_uhttp://www.oclc.org/content/dam/oclc/forms/terms/vbrl-201703.pdf
999 _c92204
_d92203